University of Texas Texas AM Investment Management Co. Makes New Investment in Catalyst Pharmaceuticals, Inc. $CPRX

University of Texas Texas AM Investment Management Co. purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 39,435 shares of the biopharmaceutical company’s stock, valued at approximately $920,000.

Several other institutional investors have also modified their holdings of CPRX. Royal Bank of Canada grew its stake in shares of Catalyst Pharmaceuticals by 39.1% in the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock worth $5,177,000 after acquiring an additional 60,040 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Catalyst Pharmaceuticals by 5.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock worth $1,749,000 after purchasing an additional 3,800 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Catalyst Pharmaceuticals by 11.9% during the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after purchasing an additional 333,100 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Catalyst Pharmaceuticals by 99.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock worth $12,763,000 after purchasing an additional 262,392 shares in the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Catalyst Pharmaceuticals by 6.5% during the first quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock worth $1,700,000 after purchasing an additional 4,261 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $31.37 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $19.05 and a 1 year high of $32.56. The company has a market capitalization of $3.84 billion, a PE ratio of 18.03, a P/E/G ratio of 0.95 and a beta of 0.74. The company has a fifty day moving average of $29.29 and a two-hundred day moving average of $25.70.

Analysts Set New Price Targets

A number of equities analysts recently commented on CPRX shares. Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $31.50 in a research note on Friday, May 8th. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Robert W. Baird downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).